At Castle, it all comes down to people. After all, disease doesn’t just happen — it happens to people. We believe that disease management and treatment decisions can be better informed through a person’s unique biology, which is revealed through the scientific rigor of our innovative tests. We are committed to empowering healthcare providers and patients with the goal of improved outcomes.
The DecisionDx-UM gene expression profile (GEP) test enables accurate determination of metastatic risk in uveal melanoma. The test identifies the molecular signature of an individual’s tumor and its likelihood of metastasis within 5 years. Specifically, the assay determines the activity or “expression” of 15 genes which indicate a patient’s individual risk, or class.
